F. Hoffmann-La Roche Ltd: New two-year data confirm Roche's Vabysmo improves vision with fewer treatments for people with neovascular age-related macular degeneration

In the TENAYA and LUCERNE studies, more than 60% of Vabysmo patients could be treated every four months at two years. This represents an increase from 45% at year one Patients treated with Vabysmo received

Related Keywords

Japan ,Ireland ,United States ,United Kingdom ,Switzerland ,America ,Irish ,American ,Nathalie Meetz ,Levi Garraway ,Birgit Masjost ,Loren Kalm ,Sabine Borngr ,Gerard Tobin ,Bruno Eschli ,Genentech ,Head Of Global Product Development ,Novartis ,Bright Focus Foundation ,Roche Group ,European Medicines Agency ,Lancet Glob Health ,Roche Group Media Relations ,Retina Specialists Annual Scientific Meeting ,Chief Medical Officer ,Global Product ,Drug Administration Approved ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Neovascular Age Related Macular Degeneration ,Durability Results From ,Age Related Macular Degeneration ,Lancet Glob ,Hoffmann ,Oche ,Ear ,Data ,Confirm ,Vabysmo ,Mproves ,Vision ,Fewer ,Treatments ,People ,Neovascular ,Elated ,Macular ,Regeneration ,